摘要
目的评价泮托拉唑、血凝酶联合奥曲肽治疗上消化道出血(UGH)的安全性。方法回顾2015年1月—2019年5月该院传染科50例UGH患者临床资料,其中以泮托拉唑联合血凝酶治疗为A组,泮托拉唑+血凝酶治疗联合用奥曲肽治疗为B组。比较两组止血效果及不良反应。结果B组止血效率100%高于A组84%,差异有统计学意义(χ^2=4.348,P<0.05);A、B两组不良反应发生率分别为8%、12%,两组比较差异无统计学意义(χ^2=0.222,P>0.05)。B组患者黑便停止时间(3.43±0.89)d、呕血停止时间(1.52±0.45)d均快于A组(4.08±0.72)d、(2.33±0.72)d,差异有统计学意义(t=4.651,5.229,P<0.05)。结论对于上消化道出血,泮托拉唑、血凝酶和奥曲肽联合应用有助于快速止血,且不良反应少,安全性高,值得推广。
Objective To evaluate the safety of pantoprazole,hemagglutinase and octreotide in the treatment of upper gastrointestinal bleeding(UGH).Methods To review the clinical data of 50 patients with UGH in our hospital from January 2015 to May 2019,including pantoprazole combined with hemagglutinase in group A and pantoprazole+hemagglutinin in combination with octreotide treatment was in group B.The hemostatic effects and adverse reactions of the two groups were compared.Results The hemostasis efficiency of group B was 100%higher than that of group A(84%),the different was statistically significant(χ^2=4.348,P<0.05);the incidence of adverse reactions in group A and group B was 8%and 12%,respectively.Comparison between the two groups,the difference was not statistically significant(χ^2=0.222,P>0.05).Group B patients with cerebral palsy stop time(3.43±0.89)d,hematemesis stop time(1.52±0.45)d were faster than group A(4.08±0.72)d,(2.33±0.72)d,the difference was statistically significant(t=4.651,5.229,P<0.05).Conclusion For upper gastrointestinal bleeding,pantoprazole,hemagglutinase and octreotide combined to help rapid hemostasis,and less adverse reactions,high safety,it is worth promoting.
作者
陈黎黎
CHEN Li-li(Department of Infectious Diseases,Third People's Hospital of Qidong,Qidong,Jiangsu Province,226200 China)
出处
《世界复合医学》
2019年第9期178-180,共3页
World Journal of Complex Medicine
关键词
泮托拉唑
血凝酶
奥曲肽
上消化道出血
不良反应
Pantoprazole
Hemagglutinase
Octreotide
Upper gastrointestinalbleeding
Adverse reactions
